Goldstream Capital Management’s State Street SPDR S&P Biotech ETF XBI Stock Holding History

Goldstream Capital Management’s Portfolio XBI Stock Details XBI Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q2	–	Sell	-500	Closed	-$47.4K	–	32
2024 Q1	$47.4K	Hold	500	–	–	0.03%	26
2023 Q4	$44.6K	Sell	500 -1,700	-77%	-$126K	0.03%	27
2023 Q3	$161K	Hold	2,200	–	–	0.13%	38
2023 Q2	$183K	Hold	2,200	–	–	0.13%	34
2023 Q1	$168K	Sell	2,200 -12,400	-85%	-$1.03M	0.18%	27
2022 Q4	$1.21M	Buy	14,600 +5,600	+62%	+$453K	1.64%	6
2022 Q3	$714K	Sell	9,000 -21,800	-71%	-$1.84M	0.55%	7
2022 Q2	$2.29M	Buy	+30,800	New	+$2.31M	1.99%	4

Other funds holding XBI

JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return

Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.55T AUM 33.47% 1-Year Est. Return

Citigroup New York $303B AUM 53.02% 1-Year Est. Return

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

BNP Paribas Financial Markets Paris, France $289B AUM 60.46% 1-Year Est. Return

Healthcare of Ontario Pension Plan (HOOPP) Trust Fund Toronto, Ontario, Canada $71.2B AUM 48.86% 1-Year Est. Return

ACA

Avoro Capital Advisors New York $11.1B AUM 207.82% 1-Year Est. Return

Wells Fargo San Francisco, California $617B AUM 30.33% 1-Year Est. Return

Canada Pension Plan Investment Board Toronto Ontario, Ontario, Canada $181B AUM 41.77% 1-Year Est. Return

Goldstream Capital Management's XBI Position: Q2 2024 in Review

Goldstream Capital Management sold out of State Street SPDR S&P Biotech ETF (XBI) in Q2 2024, closing a stake of 500 shares — an estimated $47.4K sold.

Goldstream Capital Management first reported a position in XBI in Q2 2022 and held it in 8 quarters. The position peaked at $2.29M in Q2 2022. 761 funds tracked by Wall St. Rank hold XBI as of Q2 2024.

Goldstream Capital Management reported no remaining State Street SPDR S&P Biotech ETF position as of Q2 2024 after selling out during the quarter.
Goldstream Capital Management sold 500 State Street SPDR S&P Biotech ETF shares in Q2 2024, an estimated $47.4K.
Goldstream Capital Management first reported a position in State Street SPDR S&P Biotech ETF in Q2 2022 and held it in 8 quarters.
Goldstream Capital Management's State Street SPDR S&P Biotech ETF position peaked at $2.29M in Q2 2022.
761 funds tracked by Wall St. Rank held State Street SPDR S&P Biotech ETF as of Q2 2024.

Based on Goldstream Capital Management's 13F filing for Q2 2024, filed 14 Aug 2024.